Research and Development

Exscientia, an Oxford-based drug design firm which has made headlines this year for its collaboration with GlaxoSmithKline to leverage its …

Andrew Lane, Executive Vice President of Established Pharmaceuticals at Abbott, discusses the key steps to be taken when reaching out …

Eli Lilly has unveiled Phase 3 results which reveal that its VEGF Receptor 2 antagonist Cyramza (ramucirumab) met its primary …

Despite us nearing the end of the year, the news has not been slowing down at all. Headlines across Europe …

When Roche announced that its combination treatment of Tecentriq, alongside its own drug Avastin and chemotherapy, successfully extended progression-free survival …

Sage Therapeutics’ stock rocketed after it announced that Phase 2 results for its treatment for major depressive disorder (MDD) were …

Fondation Ipsen has announced its appointment of Dr James A Levine as its new President. The organisation was set up …

A research letter published this week has suggested that the FDA initiatives to accelerate drug approvals in the US could …

We’ve finally reached the starter’s block when it comes to precision medicine approaches to prostate cancer, but Dr Matthew Hobbs, …

A Phase 3 trial looking at the use of Kisqali (ribociclib) to treat premenopausal or perimenopausal women with hormone-receptor positive, …

Roche has unveiled new Phase 3 data for its haemophilia A treatment Helimbra (emicizumab) in patients over 12 years of …

Disulfiram has been known as an anti-drinking compound for nearly seven decades. Initially, the compound was used in the vulcanisation …

Galectin Therapeutics has seen its share value almost halve after its revealed that GR-MD-02, its experimental treatment for non-alcoholic steatohepatitis …

Novartis and GSK have been taken to court by the Australian Competition and Consumer Commission (ACCC) over allegations of falsely …

In the latest boost to the UK’s life sciences strategy, GSK has committed £40 million to its work identifying new …